课题基金 / 基金详情

A reverse vaccinology approach to a bTB vaccine

A reverse vaccinology approach to a bTB vaccine
bTB 疫苗的逆向疫苗学方法
批准号:
BB/N004698/1
负责人:
Ian Jones
金额:
$183.03万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2016
资助国家:
英国
项目状态:
已结题
起止时间:
2016 至 --

项目摘要

项目成果

Ian Jones的其他基金

相似基金

相关文献

中文摘要
翻译
牛结核病(bTB)是牛分枝杆菌感染牛的结果。这种细菌在自然界中分布广泛,因为它也感染许多其他野生动物物种,因此,野生动物感染作为细菌的储存库,定期进入家畜。这样做的后果是双重的。首先,必须扑杀bTB阳性的牛,对农民及其维持牛群的能力产生连锁反应。其次,bTB是人类感染的威胁,主要是通过食用受污染的牛奶。今天,个体的bTB感染是极其罕见的,但威胁仍然存在,并且由于这些原因,bTB感染是不受欢迎的,并且需要被控制或优选地被根除。自20世纪90年代中期的历史回顾以来,獾已被确定为将bTB传播给家畜的主要途径之一,这反过来又导致试图通过獾扑杀来打破这一传播途径。这些措施只取得了有限的成功和巨大的公众关注,使传播途径的物理破坏基本上没有改变。另一种方法是接受bTB在环境中广泛传播,但通过先前的疫苗接种来预防牛感染。然而,目前还没有一种有效的牛bTB疫苗,迫切需要开发这种疫苗的新方法。一般认为,疫苗通过在靶动物中产生抗体应答来发挥作用,该抗体应答防止细菌建立初始感染。这些抗体是所有哺乳动物免疫系统的正常产物,通常与细菌的外部结合,从而防止细菌与牛细胞(通常是肺的上皮细胞)结合。由此可见,bTB的保护性成分,即产生保护性抗体反应的成分,存在于细菌表面的外部。细菌表面有许多成分,这些成分中的任何一种,或者可能是许多成分的组合,由细菌基因组编码的蛋白质,可能是有效免疫力发展所必需的。然而,目前尚不清楚究竟需要哪些。在这项研究中,我们建议生产bTB的所有表面成分,并批量测试它们诱导有效免疫应答的能力。我们建议在牛中进行这项工作,以便对我们的试验疫苗测量的反应是典型的,如果最终的疫苗用于典型的牛群中,将发现什么。我们的工作分为三个相关的部分。首先,我们将从M.牛细菌,这些细菌存在于生物体表面,并以安全有效的方式产生它们中的每一种。我们的初步计算表明,为了找到有效免疫所必需的少数蛋白质,可能需要数百种这样的蛋白质。其次,我们将使用我们的表面蛋白作为牛的试验疫苗,为了使这一过程有效,我们将使用蛋白质混合物进行这项工作,以便使用最少数量的牛。免疫后,我们将从牛身上采集血样,测试它们预防M的能力。牛传染病最后,我们将研究保护机制,以及我们所确定的各个成分如何共同为牛提供有效的免疫屏障。我们的方法是详尽的,但它有可能在bTB疫苗发现计划下划出一条线,并确定最终有效疫苗生产的候选人的最佳组合。
英文摘要
Bovine tuberculosis, bTB, is the result of the infection of cattle by the bacterium Mycobacterium bovis. The bacterium is distributed widely in nature as it also infects many other wildlife species and as a result of this, wildlife infection acts as a reservoir for the bacterium which periodically get across into domestic cattle. The consequence of this is twofold. First, cattle that are bTB positive must be culled with a knock-on effect on the farmer and his ability to maintain a herd. Second, bTB is a threat for human infection, primarily via the consumption of contaminated milk. Today bTB infection of individuals is extremely rare, but the threat remains and for these reasons bTB infection is unwelcome and needs to be controlled or, preferably, eradicated. Since a historical review in the mid-1990s, the badger has been identified as one of the major routes of transmission of bTB to domestic cattle and this, in turn, has led to attempts to break this transmission route via badger culling. These have met with only limited success and immense public concern leaving the physical breaking of the transmission route mostly unaltered. An alternative approach is to accept that bTB circulates widely in the environment but to prevent cattle infection by previous vaccination. At the present time however an effective vaccine for bTB in cattle is not available and new methods to develop such a vaccine are urgently needed. It is generally accepted that vaccines function by generating an antibody response in the target animal which prevents the bacterium from establishing the initial infection. These antibodies, which are a normal product of the immune system of all mammals, generally bind to the outside of the bacterium and so prevent it from binding to cattle cells, usually the epithelial cells of the lung. It follows that the protective components of bTB, that is, the components that will generate the antibody response that is protective, are to be found on the outside of the bacterium surface. Bacteria have many components on their surface and any, or perhaps a combination of many, of these components, proteins encoded by the bacterium genome, could be essential for the development of effective immunity. However exactly which are required is currently unknown. In this research, we propose to produce all of the surface components of bTB and to test them in batches for their ability to induce an effective immune response. We propose to do this work in cattle so that the response measured to our test vaccines is typical of what will be found if an eventual vaccine is used in typical herds. Our work breaks down into three related components. Firstly, we will identify all of those proteins from the M. bovis bacterium that are to be found on the surface of the organism and produce each of them in a safe and efficient manner. Our initial calculations suggest that several hundred such proteins may be required in order to find the few that are necessary for effective immunity. Secondly, we will use our surface proteins as test vaccines in cattle and to make this process efficient we will carry out this work with mixes of proteins so that the least number of cattle has to be used. Following the immunizations we will take blood samples from the cattle and test them for the ability to prevent M. bovis infection. Finally, we will examine the mechanism of protection and how the individual components so we have identified work together to provide the cattle with an effective barrier of immunity. Our approach is exhaustive but it has the potential to draw a line under the vaccine discovery program for bTB and to identify the best mix of candidates for eventual effective vaccine production.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.3390/v14050914
发表时间: 2022-04-27
期刊: Viruses
影响因子: --
作者: []
通讯作者:
DOI: 10.3389/fmolb.2022.889667
发表时间: 2022
期刊: Frontiers in molecular biosciences
影响因子: 5
作者: []
通讯作者:
DOI: 10.12688/wellcomeopenres.16628.1
发表时间: 2021
期刊: Wellcome open research
影响因子: --
作者: []
通讯作者:
Evaluation of M. bovis antigens in cattle in India for diagnostic and vaccine potential
  • 批准号:
    BB/V018132/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $3.38万
  • 财政年份:
    2022
  • 负责人:
    Ian Jones
  • 依托单位:
WISERD Civil Society: Changing perspectives on Civic Stratification and Civil Repair
  • 批准号:
    ES/S012435/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $809.0万
  • 财政年份:
    2019
  • 负责人:
    Ian Jones
  • 依托单位:
WISERD/Civil Society
  • 批准号:
    ES/L009099/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $791.11万
  • 财政年份:
    2014
  • 负责人:
    Ian Jones
  • 依托单位:
The identification of the disulfide bonds in HIV gp120 whose reduction is required for cell entry and their manipulation for immunogen design
  • 批准号:
    MR/J008796/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $63.0万
  • 财政年份:
    2012
  • 负责人:
    Ian Jones
  • 依托单位:
海外基金